Sentences with phrase «of oncology patients»

• Qualified and very brilliant Oncology Nurse with over fifteen years of experience in treatment of patients, interpreting analytical tests, treatment of cancer patients, customary checkup and appraisal of the oncology patients, managing patient credentials and providing counseling in health services.

This treatment is often reserved for end stage or palliative care of oncology patients, but is very effective in pain control where major organ systems or body areas are involved.

She is completing her Master of Science in nutrition with a focus on the dietary needs of oncology patients.

These relationships establish the foundation for patient access and facilitate opportunities for physician collaboration in the clinical management of oncology patients.

RNCs are integral to the process by which cutting - edge treatments move from the bench to the forefront of oncology patient care.

The role of the Medical / Laboratory Assistant is to facilitate the delivery of oncology patient care under the supervision of the licensed nurse and / or...

Not exact matches

Johnson & Johnson's cancer treatment Zytiga significantly cut the death risk for newly - diagnosed, advanced prostate cancer patients by 38 %, according to data unveiled at the ongoing American Society of Clinical Oncology (ASCO) annual meeting this weekend.

Immuno - oncology drugs have proven promising and effective for many patients; but they also don't produce a response in a sizable chunk of the patient pool and may eventually wane in efficacy.

Even though getting a drug to market typically takes ten years, Linear, in its eight years of operation, has already been involved in assisting two oncology drugs to be available for cancer patients.

For example, Watson for Oncology can summarize the key medical attributes of a cancer patient and rank the best treatment options based on the data it has access to.

It can be everything from an über - helpful call - center rep to an oncology adviser, recommending cancer treatments on the basis of a patient's genetic profile and thousands of clinical trials and medical journal articles it has analyzed.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

They say they expect next year to start up to 20 patient testing programs of such immuno - oncology drugs.

Initially, Pfizer and Merck KGaA, based in Darmstadt, Germany, plan together to conduct patient testing and seek approval of a Merck experimental drug called MSB0010718C, an immune - oncology drug in a class called anti-PD-L 1 antibodies.

IDEAYA is pioneering the next generation of biomarker - enabled synthetic lethality therapies for genetically defined patient populations and advancing an immuno - oncology pipeline targeting immuno - metabolism and innate immunity.

Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients tumor mutational burden to help inform and assess immuno - oncology treatment.

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

Not too long ago some doctors noticed an odd pattern in their oncology practices — too many of their patients, female patients that is, were suddenly getting divorced.

Matt Hanley is currently the Western Immuno - Oncology Regional Business Director for Bristol Myers Squibb, a leading worldwide oncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer pOncology Regional Business Director for Bristol Myers Squibb, a leading worldwide oncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer poncology company based out of Princeton, NJ, bringing novel, therapeutic Immuno - Oncology products to cancer pOncology products to cancer patients.

Their network of affiliated and partnered medical groups provide critical oncology services to more than 1,600 patients per day.

An expert in Radiotheraphy and Oncology, Prof. Aderemi Tajudeen Ajekigbe, has raised an alarm on the prevalence of cancer disease in the country, saying there were about two million cancer patients in Nigeria.

While justifying his call for allocation of oil block to cancer treatment, he said a Mevavoltage cancer therapy machine is available for 33 million Nigerians as against four to about 200,000 Australians, adding, «most patients have little or no access to Radiation Oncology services».

«This is a win - win - win for patients, payers, and employers,» Bekelman said, «The field of radiation oncology should be recognized for technical advances in clinical care that have achieved safe, effective, curative treatment for prostate cancer in fewer weeks.»

«To date, this series of meta - analyses represents the most comprehensive summary and synthesis of a rapidly growing area of psychosocial oncology: the role of religion and spirituality for patients and survivors managing the experience of cancer,» said Dr. Salsman.

We have estimated that up to 15 percent of patients will be candidates for dose optimization,» explained senior study author Javier F.Torres - Roca, MD, director of Clinical Research and associate member of the Department of Radiation Oncology at Moffitt.

«Although FDA approval is critically important for introducing a new screening test or algorithm, providers ultimately rely on guidance or guidelines to help them make the best decisions for their patients and want to understand advantages, disadvantages and unknowns associated with a new screening approach,» said Huh, who is a senior scientist for the UAB Comprehensive Cancer Center, Director of the UAB Division of Gynecologic Oncology, and is also a board member for both the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

By taking a high - cost drug with a low - fat meal — instead of on an empty stomach, as prescribed — prostate cancer patients could decrease their daily dose, prevent digestive issues and cut costs by 75 percent, according to a new study in the March 28, 2018, issue of the Journal of Clinical Oncology (JCO).

The guideline recommendations were developed by a multinational and multidisciplinary panel of oncology, obstetrics / gynecology, public health, cancer control, epidemiology / biostatistics, health economics, behavioral / implementation science, and patient advocacy experts, including some of the world's foremost research leaders on HPV and HPV vaccines.

Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab group had nearly double the survival rate (42 percent) of the chemotherapy patients (24 percent).

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation OPatients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Opatients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

The study, was reported Feb 13 to the 5th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO) will reduce significantly the number of HNSCC patients who currently undergo selective neck dissection (SND), a procedure which involves removing a group of lymph nodes from the neck in order to try to eradicate those which may have been reached by the cancer.

«That's because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,» says the study's senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology / Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.

The Michigan Oncology Sequencing Program (MI - ONCOSEQ) facilitates integrative sequencing analysis of tumors from patients with advanced cancers.

«This study forms the basis for future research in patients with breast cancer and offers hope for targeted therapy for patients with aggressive triple - negative inflammatory breast cancer,» said lead researcher Mateusz Opyrchal, M.D., Ph.D., Assistant Professor of Oncology at RPCI.

The shortened regimen, described online Sept. 29 in the Journal of Clinical Oncology, begins with intravenous busulfan and fludarabine, two chemotherapeutic drugs that wipe out a patient's immune system and prepare his or her body to receive donated marrow.

«Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML,» says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

«Across the country, large hospital size and non-English as a primary language predicted poor patient satisfaction scores while white race and higher education level predicted better scores,» said co-author Daniel McFarland, DO, Clinical Fellow, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai.

This research also sheds light on which patients we should watch more closely,» said lead study author Anja Mehnert, PhD, a professor of psychosocial oncology at the University of Leipzig in Germany.

The study — the largest to date assessing the mental and emotional health of patients with cancer using a fully standardized, diagnostic face - to - face interview — is published in the October 6 issue of the Journal of Clinical Oncology.

To ensure that patients can receive all recommended care, we need to recognize the financial burden of cancer and identify patients at risk for financial concerns,» says lead study author Christine M. Veenstra, M.D., M.S.H.P., clinical lecturer in hematology / oncology at the University of Michigan Medical School.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

«It has to be more of an individualized approach to the type of cancer and even the patient,» says the University of Nebraska, Omaha's Julie Vose, president of the American Society of Clinical Oncology (ASCO).

In this case, the research team visited the oncology department of a Madrid hospital and found that low white cell levels in patients were making them susceptible to life - threatening infections.

In our trial, however, the addition of radiation therapy directed at each of the cancerous areas greatly improved how patients responded to subsequent rounds of chemotherapy,» said Puneeth Iyengar, MD, PhD, lead author of the study and an assistant professor of radiation oncology at the University of Texas Southwestern Medical Center in Dallas.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

«While tumor profiling holds the promise of improved therapeutics through personalized medicine, it is important that both clinicians and patients discuss the possibilities of incidental findings prior to ordering the testing, as the findings can have serious implications for both the patient and their family members,» said Melinda Yushak, M.D., M.P.H., first author on the study and a medical oncology fellow in Yale School of Medicine.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.